Cerebrolysin and Recovery After Stroke (CARS)
Autor: | Alla Guekht, Herbert Moessler, Wolf-Dieter Heiss, Ovidiu Bajenaru, Johannes C. Vester, Edith Doppler, Volker Hoemberg, Dafin F. Muresanu, Volker W. Rahlfs, Christian Dinu Popescu, Dieter Meier |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2015 |
Předmět: |
Male
medicine.medical_specialty medicine.medical_treatment Original Contributions Clinical Sciences recovery of function Placebo rehabilitation randomized double-blind placebo-controlled trial 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Double-Blind Method Multicenter trial medicine Clinical endpoint Humans 030212 general & internal medicine Prospective Studies Amino Acids Prospective cohort study Stroke Aged Advanced and Specialized Nursing Rehabilitation business.industry Cerebrolysin Middle Aged medicine.disease stroke Confidence interval Neuroprotective Agents Treatment Outcome chemistry Anesthesia Physical therapy ComputingMethodologies_DOCUMENTANDTEXTPROCESSING Female Neurology (clinical) Cardiology and Cardiovascular Medicine business 030217 neurology & neurosurgery |
Zdroj: | Stroke; a Journal of Cerebral Circulation |
ISSN: | 1524-4628 0039-2499 |
Popis: | Supplemental Digital Content is available in the text. Background and Purpose— The aim of this trial was to investigate whether stroke patients who receive Cerebrolysin show improved motor function in the upper extremities at day 90 compared with patients who receive a placebo. Methods— This study was a prospective, randomized, double-blind, placebo-controlled, multicenter, parallel-group study. Patients were treated with Cerebrolysin (30 mL/d) or a placebo (saline) once daily for 21 days, beginning at 24 to 72 hours after stroke onset. The patients also participated in a standardized rehabilitation program for 21 days that was initiated within 72 hours after stroke onset. The primary end point was the Action Research Arm Test score on day 90. Results— The nonparametric effect size on the Action Research Arm Test score on day 90 indicated a large superiority of Cerebrolysin compared with the placebo (Mann–Whitney estimator, 0.71; 95% confidence interval, 0.63–0.79; P |
Databáze: | OpenAIRE |
Externí odkaz: |